TM4SF proteins are implicated in a variety of normal and pathological
processes that involve cell adhesion, motility, proliferation and differentiation.
For example, TM4SF proteins are associated with events such as wound
repair, platelet activation, neurite outgrowth, egg-sperm fusion, tumor-cell
metastasis and virus-induced syncytium formation. We have shown that
expression of CD9, a TM4SF protein, has significant effects on Chinese
Hamster Ovary (CHO) cell adhesion, spreading, pericellular fibronectin
matrix assembly and haptotactic motility to the extracellular matrix
protein fibronectin (FN), a protein critical in developing and maintaining
cell-matrix integrity. Additionally, the revised proposal incorporates
the use of the smooth muscle cell model system in conjunction with the
CHO cell model system.
Recent data demonstrate that
CD9 expression on smooth muscle cells facilitates cell motility in wound
healing assays and inhibits smooth muscle cell proliferation. An in
vivo model of vascular injury showed that CD9 blockade inhibited neointima
formation up to 28 days post carotid ligation injury. These new findings
support a connection between CD9 expression and response to vascular
injury. With respect to the mechanisms that drive these functions, we
have also shown that CD9 expression affects integrin b1 linkage to the
cytoskeleton suggesting that CD9 expression influences the complexes
that bind cells to FN. We have also demonstrated that CD9 expression
significantly increases cell motility via PI 3-kinase and Src dependent
pathways and that FAK and p130Cas phosphorylation states may be an integral
link to the observed cell phenotypes.
Recent Publications
The pharmacodynamics of parenteral glycoprotein IIb-IIIa Inhibitors.
Jennings LK, Jacoski MV and White MM. J Intervent Card 15(1):45-60,
2002.
Short term administration
of bFGF enhances coronary collateral development without exacerbating
atherosclerosis and balloon injury induced vasoproliferation in atherosclerotic
rabbits with acute myocardial infarction. Zhang C, Yang J, Feng J and
Jennings LK. J Lab Clin Med 140(2):119-125, 2002.
Longhurst CM, Jacobs J, White
MM, Crossno JT Jr, Fitzgerald DW, Bao J, Fitzgerald T, Raghow R and
Jennings LK. Chinese hamster ovary cell motility to fibronectin Is modulated
by the second extracellular loop of CD9: Identification of a putative
fibronectin binding site. J Biol Chem 277(36):32445-32452, 2002.
Haga JH, Slack SM and Jennings
LK. Comparison of shear-stress-induced platelet microparticle formation
and phosphatidylserine expression in the presence of aIIbb3 antagonists.
J Cardiovas Pharm 41(3):363-71, 2003.
Haga JH, Jennings LK and
Slack SM. Inhibition of shear-stress-induced platelet aggregation and
phosphotyrosine signaling by GPIIb-IIIa antagonists. Ann Biomed Eng
30(10):1262-72, 2002.
Identification of CD9 extracellular
domains important in regulation of CHO cell adhesion to fibronectin
and fibronectin pericellular matrix assembly. Cook GA, Grgurevich S
and Jennings LK. Blood 100(13):4502-4511, 2002.
Identification of CD9 extracellular
domains important in regulation of CHO cell adhesion to fibronectin
and fibronectin pericellular matrix assembly. Cook GA, Longhurst CM,
Grgurevich S, Cholera S, Crossno JT Jr, Jennings LK. Blood 100(13):4502-11,
2002.
Thiol alkylation inhibits the mitogenic effects of platelet-derived
growth factor and renders it proapototic via activation of STATS and
p53 and induction of expression of caspase 1 and p21 waf1/cip1. Bhanoori
M, Yellatura CR, Ghosh, SK, Hassid AV, Jennings, Lk and Rao GN. Oncogene
22(1):117-30, 2003.
Role of in-vitro cholesterol depletion in mediating human platelet
aggregation. Grgurevich S. and Jennings, L.K. Thrombosis and Haemostasis
1:576-586, 2003.
Interaction of myeloperoxidase with vascular NAD(P)H oxidase-derived
reactive oxygen species in vasculature: implications for vascular diseases.
Zhang C, Yang J, Jacobs J and Jennings LK. Am J Physiol Heart Circ Physiol
285:h1-h10, 2003.
Leukocyte-derived myeloperoxidase amplifies high glucose-induced vascular
dysfunction through the interaction with high glucose stimulated, vascular
nonleukocyte-derived reactive oxygen species. Zhang C, Yang J, Jennings
LK.Diabetes 53(11):2950-9. 2004.
Comparative pharmacodynamic evaluation of eptifibatide and tirofiban
HCl In patients undergoing coronary Intervention-The TAM1 Study. Saucedo,
J.F., Wolford, D.C., Cook, S.L., Ramanathan, K.B., Garza, L., Matin,
Z., McGrew, F.A., Jacoski, M.V., Jennings, L.K. Am. J. Card., 93 (10)
1270-82, 2004.
Attenuation of neointima formation through the inhibition of DNA repair
enzyme PARP-1 in balloon-injured rat carotid artery. Zhang, C., Yang,
J., and Jennings, L.K. Am J Physiol. 287: H659-H666, 2004.
Association between platelet receptor occupancy after eptifibatide
(Integrilin) therapy and patency, myocardial perfusion, and ST-segment
resolution among patients with ST-segment resolution among patients
with ST-segment elevation myocardial infarction. Gibson, C.M., Jennings,
L.K., Murphy, S.A., Lorenz, D.P., Giugliano R.P., Harrington, R.A.,
Cholera, S., Krishnan, R., Califf, R.M., Braunwald, E.Circ. 110:679-84,
2004.
Comparative pharmacodynamic evaluation of eptifibatide and abciximab
in patients with non-ST-segment elevation acute coronary syndromes:
The TAM2 Study. Saucedo J.F., Lui H.K., Garza L., Guerra G.J., Jacoski,
MV and Jennings, LK. J Thromb Thrombolysis, 18(2), 67-74, 2004.
Tetraspanin CD82 attenuates cellular morphogenesis through down-regulating
integrin a6-mediated cell adhesion. He B., Liu L., Cook G.A., Grgurevich
S., Jennings L.K. and Zhang X.A. J Biol Chem. 2005 Feb 4;280(5):3346-54.
The use of the point of care Helena ICHOR/Plateletworks® and the
Accumetrics Ultegra® RPFA for assessment of platelet function with
GPIIb-IIIa antagonists. White M.M., Krishnan R., Kueter T.J., Jacoski
M.V., and Jennings L.K. J Thromb Thrombolysis, 18(3), 163-169, 2004.
The beta3 subunit of the integrin alphaIIbbeta3 regulates alphaIIb-mediated
outside-in signaling. Liu J, Jackson CW, Gruppo RA, Jennings LK, Gartner
TK. Blood. 2005 Jun 1;105(11):4345-52.
Rapamycin-coated expanded polytetrafluoroethylene bypass grafts exhibit
decreased anastomotic neointimal hyperplasia in a porcine model. Cagiannos
C, Abul-Khoudoud OR, DeRijk W, Shell DH 4th, Jennings LK, Tolley EA,
Handorf CR, Fabian TC.J Vasc Surg. 2005 Nov;42(5):980-8.
TIMI Study Group. Comparison of Effects of Bare Metal Versus Drug-Eluting
Stent Implantation on Biomarker Levels Following Percutaneous Coronary
Intervention for Non-ST-Elevation Acute Coronary Syndrome. Gibson CM,
Karmpaliotis D, Kosmidou I, Murphy SA, Kirtane AJ, Budiu D, Ray KK,
Herrmann HC, Lakkis N, Kovach R, French W, Blankenship J, Lui HH, Palabrica
T, Jennings LK, Cohen DJ, Morrow DA. Am J Cardiol. 2006 May 15;97(10):1473-1477.
L-arginine chlorination results in the formation of a nonselective
nitric oxide synthase inhibitor. Yang J, Ji R, Cheng Y, Sun JZ, Jennings
LK and Zhang C. J Pharmacol Exp Ther. 2006 May 22. [Epub ahead of print]
[HOME] [CENTER]
[DIRECTOR] [FACULTY]
[WORKING GROUP] [INJURY
LAB] [TAM]
[TAM INVESTIGATORS]
[TAM TRIALS] [NEWS]
[GIVING]